Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report)’s share price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.00 and traded as high as $0.27. Hemispherx BioPharma shares last traded at $0.25, with a volume of 230,718 shares changing hands.
Hemispherx BioPharma Stock Performance
About Hemispherx BioPharma
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Further Reading
- Five stocks we like better than Hemispherx BioPharma
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Energy Vault Soars 100%: CEO Shares Why in MarketBeat Exclusive
- What Investors Need to Know About Upcoming IPOs
- Meta’s Q3 Earnings Beat—Is This Dip a Golden Entry Opportunity?
- Overbought Stocks Explained: Should You Trade Them?
- Top Nuclear Stocks Thriving on Soaring Energy Demand
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
